Somatostatin receptor scintigraphy and somatostatin therapy in the evaluation and treatment of malignant thymoma
Clinical Nuclear Medicine, ISSN: 0363-9762, Vol: 24, Issue: 1, Page: 24-28
1999
- 37Citations
- 2Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations37
- Citation Indexes37
- 37
- CrossRef29
- Captures2
- Readers2
Article Description
Purpose: This report illustrates the potential diagnostic and therapeutic utility of somatostatin receptor scintigraphy and therapy with somatostatin. Methods: In-111 pentetreotide (In-11 octreotide), a somatostatin analog, was used to define the receptor status and the extent of disease in a case of malignant thymoma. Results: Subsequent treatment with nonradioactive somatostatin inhibited tumor growth. Conclusion: In-111 octreotide may be useful to define tumor receptor status and may provide prognostic information useful in determining subsequent therapy.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=0032932392&origin=inward; http://dx.doi.org/10.1097/00003072-199901000-00006; http://www.ncbi.nlm.nih.gov/pubmed/9890489; http://journals.lww.com/00003072-199901000-00006; https://dx.doi.org/10.1097/00003072-199901000-00006; https://journals.lww.com/nuclearmed/Abstract/1999/01000/Somatostatin_Receptor_Scintigraphy_and.6.aspx
Ovid Technologies (Wolters Kluwer Health)
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know